Rifaximin for Preventing Acute Graft Versus Host Disease
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the feasibility of this approach; to gather preliminary data on the incidence of GVHD and other clinical outcomes; to obtain pre-clinical data on the serial plasma levels of three biologic markers- endotoxin, soluble IL-2 receptor and TNF.
1 year after last patient enrolled
John Horan, MD
United States: Institutional Review Board
|Emory University||Atlanta, Georgia 30322|
|Children's Healthcare of Atlanta||Atlanta, Georgia 30342|